Diamond-Blackfan anemia (DBA) is a rare genetic disorder affecting the bone marrow's ability to produce red blood cells, leading to severe anemia and various physical abnormalities. Approximately 75% of DBA cases involve heterozygous mutations in ribosomal protein (RP) genes, classifying it as a ribosomopathy, with RPS19 being the most frequently mutated gene. Non-RP mutations, such as in GATA1, have also been identified. Current treatments include glucocorticosteroids, blood transfusions, and hematopoietic stem cell transplantation (HSCT), with HSCT being the only curative option, albeit with challenges like donor availability and immunological complications. Gene therapy, particularly using lentiviral vectors and CRISPR/Cas9 technology, emerges as a promising alternative. This review explores the potential of gene therapy, focusing on lentiviral vectors and CRISPR/Cas9 technology in combination with non-integrating lentiviral vectors, as a curative solution for DBA. It highlights the transformative advancements in the treatment landscape of DBA, offering hope for individuals affected by this condition.

Czech Centre for Phenogenomics Institute of Molecular Genetics of the Czech Academy of Sciences v v i 252 50 Vestec Czech Republic

Laboratory of Transgenic Models of Diseases Institute of Molecular Genetics of the Czech Academy of Sciences v v i 252 50 Vestec Czech Republic

See more in PubMed

Liu Y., Karlsson S. Perspectives of current understanding and therapeutics of Diamond-Blackfan anemia. Leukemia. 2024;38:1–9. doi: 10.1038/s41375-023-02082-w. PubMed DOI PMC

Kang J., Brajanovski N., Chan K.T., Xuan J., Pearson R.B., Sanij E. Ribosomal proteins and human diseases: Molecular mechanisms and targeted therapy. Signal Transduct. Target. Ther. 2021;6:323. doi: 10.1038/s41392-021-00728-8. PubMed DOI PMC

Ulirsch J.C., Verboon J.M., Kazerounian S., Guo M.H., Yuan D., Ludwig L.S., Handsaker R.E., Abdulhay N.J., Fiorini C., Genovese G., et al. The Genetic Landscape of Diamond-Blackfan Anemia. Am. J. Hum. Genet. 2018;103:930–947. doi: 10.1016/j.ajhg.2018.10.027. PubMed DOI PMC

Maceckova Z., Kubickova A., De Sanctis J.B., Hajduch M. Effect of Glucocorticosteroids in Diamond-Blackfan Anaemia: Maybe Not as Elusive as It Seems. Int. J. Mol. Sci. 2022;23:1886. doi: 10.3390/ijms23031886. PubMed DOI PMC

Bartels M., Bierings M. How I manage children with Diamond-Blackfan anaemia. Br. J. Haematol. 2019;184:123–133. doi: 10.1111/bjh.15701. PubMed DOI PMC

Strahm B., Loewecke F., Niemeyer C.M., Albert M., Ansari M., Bader P., Bertrand Y., Burkhardt B., Da Costa L.M., Ferster A., et al. Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia. Blood Adv. 2020;4:1760–1769. doi: 10.1182/bloodadvances.2019001210. PubMed DOI PMC

Vlachos A., Muir E. How I treat Diamond-Blackfan anemia. Blood. 2010;116:3715–3723. doi: 10.1182/blood-2010-02-251090. PubMed DOI PMC

Da Costa L., Leblanc T., Mohandas N. Diamond-Blackfan Anemia. Blood. 2020;136:1262–1273. doi: 10.1182/blood.2019000947. PubMed DOI PMC

Lipton J.M., Ellis S.R. Diamond-Blackfan anemia: Diagnosis, treatment, and molecular pathogenesis. Hematol. Oncol. Clin. North. Am. 2009;23:261–282. doi: 10.1016/j.hoc.2009.01.004. PubMed DOI PMC

Jahan D., Al Hasan M.M., Haque M. Diamond-Blackfan anemia with mutation in RPS19: A case report and an overview of published pieces of literature. J. Pharm. Bioallied Sci. 2020;12:163–170. doi: 10.4103/jpbs.JPBS_234_19. PubMed DOI PMC

Danilova N., Sakamoto K.M., Lin S. Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood. 2008;112:5228–5237. doi: 10.1182/blood-2008-01-132290. PubMed DOI

Chakraborty A., Uechi T., Higa S., Torihara H., Kenmochi N. Loss of ribosomal protein L11 affects zebrafish embryonic development through a p53-dependent apoptotic response. PLoS ONE. 2009;4:e4152. doi: 10.1371/journal.pone.0004152. PubMed DOI PMC

Moniz H., Gastou M., Leblanc T., Hurtaud C., Cretien A., Lecluse Y., Raslova H., Larghero J., Croisille L., Faubladier M., et al. Primary hematopoietic cells from DBA patients with mutations in RPL11 and RPS19 genes exhibit distinct erythroid phenotype in vitro. Cell Death Dis. 2012;3:e356. doi: 10.1038/cddis.2012.88. PubMed DOI PMC

Rio S., Gastou M., Karboul N., Derman R., Suriyun T., Manceau H., Leblanc T., El Benna J., Schmitt C., Azouzi S., et al. Regulation of globin-heme balance in Diamond-Blackfan anemia by HSP70/GATA1. Blood. 2019;133:1358–1370. doi: 10.1182/blood-2018-09-875674. PubMed DOI PMC

Mills E.W., Green R. Ribosomopathies: There’s strength in numbers. Science. 2017;358:eaan2755. doi: 10.1126/science.aan2755. PubMed DOI

Ludwig L.S., Gazda H.T., Eng J.C., Eichhorn S.W., Thiru P., Ghazvinian R., George T.I., Gotlib J.R., Beggs A.H., Sieff C.A., et al. Altered translation of GATA1 in Diamond-Blackfan anemia. Nat. Med. 2014;20:748–753. doi: 10.1038/nm.3557. PubMed DOI PMC

Iskander D., Wang G., Heuston E.F., Christodoulidou C., Psaila B., Ponnusamy K., Ren H., Mokhtari Z., Robinson M., Chaidos A., et al. Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia. Sci. Transl. Med. 2021;13:eabf0113. doi: 10.1126/scitranslmed.abf0113. PubMed DOI

Narla A., Vlachos A., Nathan D.G. Diamond Blackfan anemia treatment: Past, present, and future. Semin. Hematol. 2011;48:117–123. doi: 10.1053/j.seminhematol.2011.01.004. PubMed DOI PMC

Bhoopalan S.V., Suryaprakash S., Sharma A., Wlodarski M.W. Hematopoietic cell transplantation and gene therapy for Diamond-Blackfan anemia: State of the art and science. Front. Oncol. 2023;13:1236038. doi: 10.3389/fonc.2023.1236038. PubMed DOI PMC

Sutton R.E., Reitsma M.J., Uchida N., Brown P.O. Transduction of Human Progenitor Hematopoietic Stem Cells by Human Immunodeficiency Virus Type 1-Based Vectors Is Cell Cycle Dependent. J. Virol. 1999;73:3649–3660. doi: 10.1128/jvi.73.5.3649-3660.1999. PubMed DOI PMC

Peluffo H., Foster E., Ahmed S.G., Lago N., Hutson T.H., Moon L., Yip P., Wanisch K., Caraballo-Miralles V., Olmos G., et al. Efficient gene expression from integration-deficient lentiviral vectors in the spinal cord. Gene Ther. 2013;20:645–657. doi: 10.1038/gt.2012.78. PubMed DOI

Kalidasan V., Ng W.H., Ishola O.A., Ravichantar N., Tan J.J., Das K.T. A guide in lentiviral vector production for hard-to-transfect cells, using cardiac-derived c-kit expressing cells as a model system. Sci. Rep. 2021;11:19265. doi: 10.1038/s41598-021-98657-7. PubMed DOI PMC

Jang Y., Kim Y.S., Wielgosz M.M., Ferrara F., Ma Z., Condori J., Palmer L.E., Zhao X., Kang G., Rawlings D.J., et al. Optimizing lentiviral vector transduction of hematopoietic stem cells for gene therapy. Gene Ther. 2020;27:545–556. doi: 10.1038/s41434-020-0150-z. PubMed DOI PMC

Schlimgen R., Howard J., Wooley D., Thompson M., Baden L.R., Yang O.O., Christiani D.C., Mostoslavsky G., Diamond D.V., Duane E.G., et al. Risks Associated with Lentiviral Vector Exposures and Prevention Strategies. J. Occup. Env. Med. 2016;58:1159–1166. doi: 10.1097/JOM.0000000000000879. PubMed DOI PMC

Howe S.J., Mansour M.R., Schwarzwaelder K., Bartholomae C., Hubank M., Kempski H., Brugman M.H., Pike-Overzet K., Chatters S.J., de Ridder D., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Investig. 2008;118:3143–3150. doi: 10.1172/JCI35798. PubMed DOI PMC

Flygare J., Aspesi A., Bailey J.C., Miyake K., Caffrey J.M., Karlsson S., Ellis S.R. Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits. Blood. 2006;109:980–986. doi: 10.1182/blood-2006-07-038232. PubMed DOI PMC

Hamaguchi I., Flygare J., Nishiura H., Brun A.C., Ooka A., Kiefer T., Ma Z., Dahl N., Richter J., Karlsson S. Proliferation deficiency of multipotent hematopoietic progenitors in ribosomal protein S19 (RPS19)-deficient diamond-Blackfan anemia improves following RPS19 gene transfer. Mol. Ther. 2003;7:613–622. doi: 10.1016/s1525-0016(03)00091-1. PubMed DOI

Jaako P., Debnath S., Olsson K., Modlich U., Rothe M., Schambach A., Flygare J., Karlsson S. Gene therapy cures the anemia and lethal bone marrow failure in a mouse model of RPS19-deficient Diamond-Blackfan anemia. Haematologica. 2014;99:1792–1798. doi: 10.3324/haematol.2014.111195. PubMed DOI PMC

Debnath S., Jaako P., Siva K., Rothe M., Chen J., Dahl M., Gaspar H.B., Flygare J., Schambach A., Karlsson S. Lentiviral Vectors with Cellular Promoters Correct Anemia and Lethal Bone Marrow Failure in a Mouse Model for Diamond-Blackfan Anemia. Mol. Ther. 2017;25:1805–1814. doi: 10.1016/j.ymthe.2017.04.002. PubMed DOI PMC

Liu Y., Dahl M., Debnath S., Rothe M., Smith E.M., Grahn T.H.M., Warsi S., Chen J., Flygare J., Schambach A., et al. Successful gene therapy of Diamond-Blackfan anemia in a mouse model and human CD34(+) cord blood hematopoietic stem cells using a clinically applicable lentiviral vector. Haematologica. 2022;107:446–456. doi: 10.3324/haematol.2020.269142. PubMed DOI PMC

Voit R.A., Liao X., Cohen B., Armant M., Kamal E., Huang M.-M., Clarke W., Williams D.A., Shimamura A., Sankaran V.G. Regulated Expression of GATA1 As a Gene Therapy Cure for Diamond-Blackfan Anemia. Blood. 2022;140:986–987. doi: 10.1182/blood-2022-165848. DOI

Gene Transfer For Patients with Sickle Cell Disease Using A Gamma Globin Lentivirus Vector: An Open-Label Phase 1/2 Pilot Study, NCT02186418. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT02186418?cond=Sickle%20Cell%20Disease&term=lentivirus%20gene%20therapy%20&rank=1.

Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Sickle Cell Disease, NCT03282656. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT03282656?cond=Sickle%20Cell%20Disease&term=lentivirus%20gene%20therapy%20&rank=2.

A Multi-Center, Phase 2 Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell (GRASP, BMT CTN 2001), NCT05353647. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT05353647?cond=Sickle%20Cell%20Disease&term=lentivirus%20gene%20therapy%20&rank=3.

Clinical Research Study of Autologous Stem Cell Transplantation for Sickle Cell Disease (SCD) Using Peripheral Blood CD34+ Cells Modified with the Lenti/G-βAS3-FB Lentiviral Vector, NCT02247843. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT02247843?cond=Sickle%20Cell%20Disease&term=lentivirus%20gene%20therapy%20&rank=4.

A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced Ex Vivo with the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene (GLOBE1 βAS3 Modified Autologous CD34+ Cells) in Patients with Sickle Cell Disease (SCD), NCT03964792. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT03964792?cond=Sickle%20Cell%20Disease&term=lentivirus%20gene%20therapy%20&rank=5.

A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the β-Hemoglobinopathies (Sickle Cell Anemia and β-Thalassemia Major) by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral β-A-T87Q Globin Vector (LentiGlobin BB305 Drug Product), NCT02151526. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT02151526?cond=Sickle%20Cell%20Disease&term=lentivirus%20gene%20therapy%20&rank=6.

Evaluation of Safety and Efficacy of Transplantation of Autologous Hematopoietic Stem Cell Genetically Modified in Beta-Thalassemia Major, NCT03276455. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT03276455?cond=Thalassemia&term=lentivirus%20gene%20therapy%20&rank=3.

A Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem Cells Genetically Modified with GLOBE Lentiviral Vector Encoding for the Human Beta-Globin Gene for the Treatment of Patients Affected by Transfusion Dependent Beta-Thalassemia, NCT02453477. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT02453477?cond=Thalassemia&term=lentivirus%20gene%20therapy%20&rank=4.

Evaluation of the Safety and Efficacy of KL003 Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia with No Conditioning Regimen, NCT06219239. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT06219239?cond=Thalassemia&term=lentivirus%20gene%20therapy%20&rank=6.

Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-Thalassemia Major Patients, NCT05745532. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT05745532?cond=Thalassemia&term=lentivirus%20gene%20therapy%20&rank=7.

A Phase I/II Clinical Study Evaluating the Safety and Efficacy of KL003 Cell Injection in Transfusion-Dependent β-Thalassemia, NCT06280378. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT06280378?cond=Thalassemia&term=lentivirus%20gene%20therapy%20&rank=8.

A Phase I Clinical Trial for the Treatment of ß-Thalassemia Major with Autologous CD34+ Hematopoietic Progenitor Cells Transduced with TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene, NCT01639690. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT01639690?cond=Thalassemia&term=lentivirus%20gene%20therapy%20&rank=9.

An Open Label Study Evaluating the Safety and Efficacy of Gene Therapy for Transfusion-Dependent β-Thalassemia by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a LentiRed Lentiviral Vector (GMCN-508B Drug Product, Also Called LentiRed), NCT05762510. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT05762510?cond=Thalassemia&term=lentivirus%20gene%20therapy%20&rank=11.

A Phase 1 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects with Transfusion-Dependent α-Thalassemia by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo with a Lentiviral Vector (GMCN-508A Drug Product), NCT05757245. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT05757245?cond=Thalassemia&term=lentivirus%20gene%20therapy%20&rank=12.

A Phase 1 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects with β-Thalassemia Major by Transplantation of Autologous CD34+Stem Cells Transduced with a Lentiviral Vector Encoding βA-T87Q-Globin, NCT05015920. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT05015920?cond=Thalassemia&term=lentivirus%20gene%20therapy%20&rank=13.

Gene Transfer for Patients with Fanconi Anemia Complementation Group A (FANCA), NCT01331018. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT01331018?cond=Fanconi%20Anemia&term=lentivirus%20gene%20therapy%20&rank=1.

Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene in Patients with Fanconi Anaemia Subtype A: FANCOLEN-I, NCT04437771. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT04437771?cond=Fanconi%20Anemia&term=lentivirus%20gene%20therapy%20&rank=2.

Luis A. The Old and the New: Prospects for Non-Integrating Lentiviral Vector Technology. Viruses. 2020;12:1103. doi: 10.3390/v12101103. PubMed DOI PMC

Gurumoorthy N., Nordin F., Tye G.J., Wan Kamarul Zaman W.S., Ng M.H. Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through. Biomedicines. 2022;10:107. doi: 10.3390/biomedicines10010107. PubMed DOI PMC

Milone M.C., O’Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32:1529–1541. doi: 10.1038/s41375-018-0106-0. PubMed DOI PMC

Shaw A., Cornetta K. Design and Potential of Non-Integrating Lentiviral Vectors. Biomedicines. 2014;2:14–35. doi: 10.3390/biomedicines2010014. PubMed DOI PMC

Wienert B., Cromer M.K. CRISPR nuclease off-target activity and mitigation strategies. Front. Genome Ed. 2022;4:1050507. doi: 10.3389/fgeed.2022.1050507. PubMed DOI PMC

Hunt J.M.T., Samson C.A., Rand A.D., Sheppard H.M. Unintended CRISPR-Cas9 editing outcomes: A review of the detection and prevalence of structural variants generated by gene-editing in human cells. Hum. Genet. 2023;142:705–720. doi: 10.1007/s00439-023-02561-1. PubMed DOI PMC

Kantor A., McClements M.E., MacLaren R.E. CRISPR-Cas9 DNA Base-Editing and Prime-Editing. Int. J. Mol. Sci. 2020;21:6240. doi: 10.3390/ijms21176240. PubMed DOI PMC

Hryhorowicz M., Lipinski D., Zeyland J. Evolution of CRISPR/Cas Systems for Precise Genome Editing. Int. J. Mol. Sci. 2023;24:4233. doi: 10.3390/ijms241814233. PubMed DOI PMC

Jeong Y.K., Song B., Bae S. Current Status and Challenges of DNA Base Editing Tools. Mol. Ther. 2020;28:1938–1952. doi: 10.1016/j.ymthe.2020.07.021. PubMed DOI PMC

Lu C., Kuang J., Shao T., Xie S., Li M., Zhu L., Zhu L. Prime Editing: An All-Rounder for Genome Editing. Int. J. Mol. Sci. 2022;23:9862. doi: 10.3390/ijms23179862. PubMed DOI PMC

Mishra R., Joshi R.K., Zhao K. Base editing in crops: Current advances, limitations and future implications. Plant Biotechnol. J. 2020;18:20–31. doi: 10.1111/pbi.13225. PubMed DOI PMC

Porto E.M., Komor A.C., Slaymaker I.M., Yeo G.W. Base editing: Advances and therapeutic opportunities. Nat. Rev. Drug Discov. 2020;19:839–859. doi: 10.1038/s41573-020-0084-6. PubMed DOI PMC

Collias D., Beisel C.L. CRISPR technologies and the search for the PAM-free nuclease. Nat. Commun. 2021;12:555. doi: 10.1038/s41467-020-20633-y. PubMed DOI PMC

Aldag P., Welzel F., Jakob L., Schmidbauer A., Rutkauskas M., Fettes F., Grohmann D., Seidel R. Probing the stability of the SpCas9-DNA complex after cleavage. Nucleic Acids Res. 2021;49:12411–12421. doi: 10.1093/nar/gkab1072. PubMed DOI PMC

Uchida N., Drysdale C.M., Nassehi T., Gamer J., Yapundich M., DiNicola J., Shibata Y., Hinds M., Gudmundsdottir B., Haro-Mora J.J., et al. Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease. Mol. Ther. Methods Clin. Dev. 2021;21:121–132. doi: 10.1016/j.omtm.2021.02.022. PubMed DOI PMC

Clinical Study on the Safety and Efficacy of a Single Intravenous Dose of CRISPR/Cas9-Edited Autologous CD34+ Hematopoietic Stem/Progenitor Cells (BRL-101) in the Treatment of Sickle Cell Disease, NCT06287099. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT06287099?cond=Sickle%20Cell%20Disease&intr=CRISPR%2FCas9&rank=1.

A Phase I/II Study of Nula-cel in Autologous CD34+ Hematopoietic Stem Cells to Convert HbS to HbA for Treating Severe Sickle Cell Disease, NCT04819841. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT04819841?cond=Sickle%20Cell%20Disease&intr=CRISPR%2FCas9&rank=4.

A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects with Severe Sickle Cell Disease, NCT03745287. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT03745287?cond=Sickle%20Cell%20Disease&intr=CRISPR%2FCas9&rank=5.

A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects with Severe Sickle Cell Disease, βS/βC Genotype, NCT05951205. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT05951205?cond=Sickle%20Cell%20Disease&intr=CRISPR%2FCas9&rank=7.

Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease, NCT04774536. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT04774536?cond=Sickle%20Cell%20Disease&intr=CRISPR%2FCas9&rank=8.

A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects with Severe Sickle Cell Disease, NCT05329649. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT05329649?cond=Sickle%20Cell%20Disease&intr=CRISPR%2FCas9&rank=10.

A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects with Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease, NCT05477563. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT05477563?cond=Thalassemia&intr=CRISPR%2FCas9&rank=2.

A Long-term Follow-up Study of Subjects with β-Thalassemia or Sickle Cell Disease Treated with Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001), NCT04208529. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT04208529?cond=Thalassemia&intr=CRISPR%2FCas9&rank=7.

A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects with Transfusion-Dependent β-Thalassemia, NCT03655678. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT03655678?cond=Thalassemia&intr=CRISPR%2FCas9&rank=1.

A Multicenter, Open Label Phase 1 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects with Transfusion Dependent β-Thalassaemia, NCT04925206. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT04925206?cond=Thalassemia&intr=CRISPR%2FCas9&rank=3.

A Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of BRL-101 in Subjects with Transfusion-Dependent β-Thalassemia, NCT05577312. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT05577312?cond=Thalassemia&intr=CRISPR%2FCas9&rank=4.

A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects with Transfusion-Dependent β-Thalassemia, NCT05356195. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT05356195?cond=Thalassemia&intr=CRISPR%2FCas9&rank=5.

A Safety and Efficacy Study of a Single Center, Open-Label, Single Arm About the Gene Correction of HBB in Patient-Specific iHSCs Using CRISPR/Cas9 That Intervent Subjests with β-Thalassemia Mutations, NCT03728322. [(accessed on 17 April 2024)]; Available online: https://clinicaltrials.gov/study/NCT03728322?cond=Thalassemia&intr=CRISPR%2FCas9&rank=6.

Frangoul H., Altshuler D., Cappellini M.D., Chen Y.S., Domm J., Eustace B.K., Foell J., de la Fuente J., Grupp S., Handgretinger R., et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia. N. Engl. J. Med. 2021;384:252–260. doi: 10.1056/NEJMoa2031054. PubMed DOI

Newby G.A., Yen J.S., Woodard K.J., Mayuranathan T., Lazzarotto C.R., Li Y., Sheppard-Tillman H., Porter S.N., Yao Y., Mayberry K., et al. Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature. 2021;595:295–302. doi: 10.1038/s41586-021-03609-w. PubMed DOI PMC

Li C., Georgakopoulou A., Newby G.A., Chen P.J., Everette K.A., Paschoudi K., Vlachaki E., Gil S., Anderson A.K., Koob T., et al. In vivo HSC prime editing rescues sickle cell disease in a mouse model. Blood. 2023;141:2085–2099. doi: 10.1182/blood.2022018252. PubMed DOI PMC

FDA FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. [(accessed on 14 May 2024)]; Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease.

Mohammadian Gol T., Zahedipour F., Trosien P., Urena-Bailen G., Kim M., Antony J.S., Mezger M. Gene therapy in pediatrics—Clinical studies and approved drugs (as of 2023) Life Sci. 2024;348:122685. doi: 10.1016/j.lfs.2024.122685. PubMed DOI

ZYNTEGLO ZYNTEGLO™ Mechanism of Action. [(accessed on 14 May 2024)]. Available online: https://www.zynteglohcp.com/mechanism-of-action.

FDA Long Term Follow-up After Administration of Human Gene Therapy Products. [(accessed on 14 May 2024)]; Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/long-term-follow-after-administration-human-gene-therapy-products.

Lee N.K., Chang J.W. Manufacturing Cell and Gene Therapies: Challenges in Clinical Translation. Ann. Lab. Med. 2024;44:314–323. doi: 10.3343/alm.2023.0382. PubMed DOI PMC